Medicare denials for Zepbound\u00ae are frustrating because the rules changed in late 2024 and most prescribers and pharmacists haven’t caught up. In December 2024, the FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. That created a new Medicare coverage pathway that didn’t exist for tirzepatide before.<\/p>\n
If Zepbound was prescribed for weight loss alone, Medicare Part D legally can’t cover it. The Medicare Modernization Act of 2003 still bars coverage of drugs for weight loss. If Zepbound was prescribed for OSA in a patient with obesity, coverage is now possible but requires specific documentation. And if you have type 2 diabetes, you should probably be on Mounjaro\u00ae (same molecule, diabetes indication) rather than Zepbound.<\/p>\n
Let’s walk through exactly what to do when the denial letter arrives.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The default Medicare position is that Zepbound is a weight-loss drug, and Part D can’t cover weight-loss drugs under federal law.<\/strong> So a prescription submitted with an obesity diagnosis (E66.x) without any qualifying secondary indication gets auto-denied at the PBM level. About 80% of Zepbound denials in 2025 fell into this bucket according to PBM denial reason data.<\/p>\n Quick Answer: Medicare Part D cannot cover Zepbound for weight loss alone, but can cover it for moderate-to-severe OSA in patients with obesity following the December 2024 FDA approval<\/p>\n Other denial reasons include missing OSA diagnosis documentation for OSA claims, missing sleep study results, prescriber not enrolled in Medicare, step therapy not completed, quantity limits exceeded, and prior authorization not on file. Some denials are simply because the prescriber wrote “Zepbound” when the patient has diabetes and the correct drug would be Mounjaro.<\/p>\n The denial letter (called a Coverage Determination Notice) will list the specific denial reason. Read it carefully before choosing your appeal strategy.<\/p>\n Yes, after the FDA approved tirzepatide for moderate-to-severe OSA in adults with obesity in December 2024.<\/strong> The SURMOUNT-OSA trial enrolled patients with moderate-to-severe OSA (AHI 15+) and BMI of 30 or higher, and showed substantial AHI reduction over 52 weeks compared to placebo. CMS has signaled coverage through Part D for the OSA indication, though specific plan implementations vary in 2026.<\/p>\n To qualify, your prescription needs to include an OSA diagnosis code (G47.33 for obstructive sleep apnea) and obesity (E66.x with BMI 30+). You also need documented OSA severity from a sleep study, typically PSG or home sleep apnea test showing AHI of 15 or higher (moderate-to-severe).<\/p>\n Some Part D plans are still updating their PA criteria for the OSA indication in mid-2026, which is causing inconsistent coverage. Call your plan and ask specifically: “Do you cover Zepbound for OSA following the December 2024 FDA approval?”<\/p>\n Step one is requesting a coverage determination if you haven’t already.<\/strong> This is the formal request submitted by your prescriber or pharmacy. If denied, you receive a written denial notice that includes appeal instructions.<\/p>\n Step two is filing a level 1 redetermination within 60 days of the denial. This is reviewed by your Part D plan. Decision time: 7 days standard, 72 hours expedited.<\/p>\n Step three, if denied again, is filing a level 2 reconsideration with the Independent Review Entity (IRE) within 60 days. The IRE is a contractor outside your plan. Decision time: 14 days standard, 72 hours expedited.<\/p>\n Step four is administrative law judge hearing if the case meets the dollar threshold (around $190 in 2026), filed within 60 days of the IRE decision.<\/p>\n Step five and six are Medicare Appeals Council and federal court. Most cases are resolved at level 1 or 2.<\/p>\n For an OSA-pathway appeal, include four key documents.<\/strong> A letter of medical necessity citing the SURMOUNT-OSA trial and the FDA’s December 2024 OSA approval. Sleep study results showing AHI of 15+ (moderate-to-severe OSA). BMI documentation confirming the 30+ threshold. And documentation of any prior OSA therapies attempted, including CPAP adherence data.<\/p>\n For weight-loss-only denials, there’s no medical-necessity pathway that wins on appeal under current Medicare law. Pursue the OSA pathway if you have an OSA diagnosis, the diabetes pathway through Mounjaro if you have T2DM, or pivot to a cash-pay option.<\/p>\n The letter of medical necessity should specifically state that the prescription is for moderate-to-severe OSA under the FDA’s December 2024 approval, not for weight loss. Cite the SURMOUNT-OSA trial by name. Include sleep study results and CPAP intolerance or failure history if applicable.<\/p>\n Both opened Medicare coverage for drugs that were previously blocked.<\/strong> The Wegovy CV pathway requires established cardiovascular disease (prior MI, stroke, or PAD) plus BMI 27+, based on the SELECT trial. The Zepbound OSA pathway requires moderate-to-severe OSA (AHI 15+) plus BMI 30+, based on SURMOUNT-OSA. Both require the prescription to be coded for the qualifying condition, not for weight loss.<\/p>\n Tirzepatide does not yet have an FDA cardiovascular indication. The SURMOUNT-MMO trial is studying tirzepatide for cardiovascular outcomes in obesity and is expected to read out in 2027. Until then, Zepbound has only the obesity and OSA indications, and only OSA is Medicare-coverable.<\/p>\n If you have both CVD and OSA, your prescriber may have to choose which drug to prescribe based on which condition is more likely to drive a successful appeal.<\/p>\n You should be on Mounjaro, not Zepbound.<\/strong> Mounjaro is tirzepatide formulated for type 2 diabetes and is the standard Part D-coverable form for diabetic patients. Coverage for Mounjaro is straightforward with PA in most plans: A1C 7.0%+, prior metformin trial, and clinical documentation.<\/p>\n The SURPASS trials (NEJM 2021-2022) established tirzepatide’s efficacy for T2DM with A1C reductions of 1.8 to 2.4% at higher doses, larger than any other diabetes drug. Mounjaro is covered as a Tier 2 or Tier 3 drug on most Part D formularies.<\/p>\n If you have both T2DM and obesity, talk to your prescriber about whether Mounjaro is the better path. Many patients who were inappropriately prescribed Zepbound get coverage easily once switched to Mounjaro.<\/p>\n Key Takeaway: Tirzepatide for diabetes is covered as Mounjaro under most Part D plans with PA, not as Zepbound<\/p>\n At level 1, request a level 2 IRE reconsideration.<\/strong> At level 2, request an ALJ hearing if your case exceeds the dollar threshold. Most successful Zepbound appeals require the OSA pathway documentation be airtight: sleep study, AHI 15+, BMI 30+, prior CPAP history.<\/p>\n A 2024 Office of Medicare Hearings and Appeals report found ALJ overturn rates around 45% for Part D appeals, but that data predates the OSA indication so 2026 data may differ. The general rule is that appeals with strong documentation overturn more often than appeals with sparse documentation.<\/p>\n If all appeals fail, consider switching plans during AEP (October 15 to December 7) to a plan with better GLP-1 coverage. Some Medicare Advantage Special Needs Plans offer supplemental obesity benefits beyond standard Part D.<\/p>\n Three realistic paths.<\/strong> Eli Lilly’s LillyDirect program sells Zepbound vials for around $549\/month for the 2.5 mg starter dose and $549-799 for higher doses, no insurance needed. The manufacturer savings card doesn’t apply to Medicare patients per CMS anti-kickback rules, so the cash price is the real price.<\/p>\n Compounded tirzepatide through licensed telehealth providers like TrimRx runs $300-450 per month. The FDA removed tirzepatide from the drug shortage list in October 2024, restricting 503B mass compounding. 503A pharmacies can still compound personalized formulations for individual patients with valid prescriptions.<\/p>\n The third option is staying on whatever GLP-1 was coverable for a different indication (Mounjaro for diabetes, Wegovy for CV disease). This requires having one of those conditions.<\/p>\n A personalized treatment plan should consider your insurance status, comorbidities, and budget rather than defaulting to one approach.<\/p>\n Medicare Advantage Part D plans operate under the same federal restrictions on weight-loss drug coverage.<\/strong> They can cover Zepbound for OSA under the December 2024 FDA approval. Some MA plans, especially Chronic Condition Special Needs Plans (C-SNPs) for diabetes or cardiovascular disease, offer expanded GLP-1 access through supplemental benefits.<\/p>\n During the Annual Election Period (October 15 to December 7), use the Medicare Plan Finder to compare formularies. Plans that excluded Zepbound in 2025 may have added it for 2026 OSA coverage. Plans change yearly.<\/p>\n Yes, but you pay cash.<\/strong> Medicare doesn’t reimburse compounded medications because they aren’t FDA-approved drugs. Licensed telehealth providers prescribe compounded tirzepatide through 503A pharmacies for patients without coverage. Pricing typically runs $300-450 per month.<\/p>\n Tirzepatide is no longer on the FDA shortage list as of October 2024, so 503B outsourcing facility compounding is restricted. 503A patient-specific compounding remains available with a valid prescription. TrimRx and similar providers operate within this regulatory framework.<\/p>\n A free assessment quiz determines clinical fit before any prescription is written. Compounded therapy isn’t appropriate for every patient, especially those with significant cardiovascular disease who might benefit more from the FDA-approved branded products with their accompanying trial data.<\/p>\n Bottom line: Manufacturer cash program (LillyDirect $549\/month for Zepbound vials) and compounded tirzepatide ($300-450\/month) are realistic alternatives when appeals fail<\/p>\n Not for weight loss alone. The federal Medicare Modernization Act of 2003 bars Part D coverage of weight-loss drugs. Coverage is only available through the OSA indication (December 2024) or, for semaglutide, the CV indication (March 2024).<\/p>\n A polysomnogram (PSG) sleep study or home sleep apnea test (HSAT) showing AHI of 15 events per hour or higher. Some plans accept respiratory event index (REI) from HSAT in lieu of AHI. The study must be relatively recent (usually within 2-5 years depending on plan).<\/p>\n Document CPAP intolerance or failure in your appeal. Plans favor coverage when patients have failed conservative therapy. The FDA OSA indication doesn’t require CPAP failure, but Part D plans may add it as a coverage criterion.<\/p>\n Standard level 1 takes 7 days. Expedited level 1 takes 72 hours. Level 2 IRE takes 14 days standard, 72 hours expedited. ALJ hearings take up to 90 days.<\/p>\n Yes, with PA, for type 2 diabetes. Mounjaro is on most Part D formularies as Tier 2 or Tier 3. Standard PA criteria include A1C 7.0%+ and prior metformin use (or contraindication).<\/p>\n Yes. MA Part D appeals follow the same five-level process as standalone Part D. File within 60 days of the denial through your MA plan’s appeals process.<\/p>\n If TROA passes Congress, it would amend the Medicare Modernization Act to allow Part D coverage of obesity drugs. The bill has been introduced repeatedly since 2013 and has bipartisan support but hasn’t passed as of mid-2026.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Medicare denials for Zepbound are frustrating because the rules changed in late 2024 and most prescribers and pharmacists haven’t caught up.<\/p>\n","protected":false},"author":11,"featured_media":93129,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"What to Do When Medicare Denies Zepbound: Step-by-Step Appeal","_yoast_wpseo_metadesc":"Medicare denials for Zepbound are frustrating because the rules changed in late 2024 and most prescribers and pharmacists haven't caught up.","_yoast_wpseo_focuskw":"medicare denies zepbound","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[14],"tags":[23,30,58],"class_list":["post-90203","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zepbound","tag-cost-coverage","tag-insurance","tag-zepbound"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90203"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90203\/revisions"}],"predecessor-version":[{"id":91653,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90203\/revisions\/91653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93129"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Can Medicare Cover Zepbound for Sleep Apnea?<\/h2>\n
What’s the Step-by-step Medicare Appeal Process?<\/h2>\n
What Documentation Does My Zepbound Appeal Need?<\/h2>\n
How Does the OSA Pathway Differ From the CV Pathway for Wegovy\u00ae?<\/h2>\n
What If I Have Type 2 Diabetes?<\/h2>\n
What If My Appeal Is Denied?<\/h2>\n
What Are My Cash-pay Options If Appeals Fail?<\/h2>\n
Does Medicare Advantage Cover Zepbound Differently?<\/h2>\n
Can I Use Compounded Tirzepatide If Medicare Won’t Cover Zepbound?<\/h2>\n
FAQ<\/h2>\n
Can Medicare Cover Zepbound for Weight Loss in 2026?<\/h3>\n
How Do I Prove I Have Moderate-to-severe OSA?<\/h3>\n
What If I Can’t Tolerate CPAP and That’s Why I Want Zepbound?<\/h3>\n
How Long Does a Medicare Zepbound Appeal Take?<\/h3>\n
Does Medicare Cover Mounjaro?<\/h3>\n
Can I Appeal If My Medicare Advantage Plan Denied Zepbound?<\/h3>\n
Will the Treat and Reduce Obesity Act Change This?<\/h3>\n